Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00350662
Recruitment Status : Completed
First Posted : July 11, 2006
Last Update Posted : November 19, 2012
Sponsor:
Information provided by (Responsible Party):
Lipomed

Tracking Information
First Submitted Date  ICMJE July 10, 2006
First Posted Date  ICMJE July 11, 2006
Last Update Posted Date November 19, 2012
Study Start Date  ICMJE January 2002
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE
 (submitted: November 16, 2012)
Clinical efficacy (Iron balance and liver iron concentration) [ Time Frame: At baseline and at 12 months ]
Original Primary Outcome Measures  ICMJE
 (submitted: July 10, 2006)
Clinical efficacy (Iron balance and liver iron concentration) at 12 months
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 16, 2012)
  • Safety profile (general, hematologic, and organ toxicity) [ Time Frame: At 3-monthly intervals ]
  • Liver histology [ Time Frame: At baseline and at 12 months ]
  • Quality of life (patient's subjective of compliance and tolerance) [ Time Frame: At 3-monthly intervals ]
  • Actual treatment duration (ATD) [ Time Frame: At 12 months ]
Original Secondary Outcome Measures  ICMJE
 (submitted: July 10, 2006)
  • Serum ferritin at 3-monthly intervals
  • Safety profile (general, hematologic, and organ toxicity) at 3-monthly intervals
  • Liver histology at 12 months
  • Quality of life (patient's subjective of compliance and tolerance) at 3-monthly intervals
  • Actual treatment duration (ATD)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Official Title  ICMJE Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Brief Summary Comparison of efficacy and toxicity of the combination treatment of deferiprone and desferrioxamine with the single agent treatment of either drug
Detailed Description

Patients with refractory anemias requiring regular blood transfusions accumulate iron at the rate of approximately 0.5 mg/kg/day, which may lead to serious organ toxicity. The human body has no active mechanism for the excretion of excess iron. Therefore multiply transfused patients will develop a secondary hemosiderosis, if no iron excretion is achieved by a chelating agent. Symptoms of iron-overload occur when body iron stores reach 10-20 g. At higher levels severe, even fatal complications, particularly cardiac failure, may develop.

Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug, but is expensive and must be given by slow subcutaneous or intravenous infusion for 8-12 hours a day during 5-7 days weekly at a dosage of 40-50mg/kg body weight/day. This often leads to failure of compliance of the patient and therefore to inefficient iron chelation. Further some patients are hypersensitive to desferrioxamine and others suffer from toxicity, e.g. to the ears or eyes.

Deferiprone (L1; CP20; 1,2 dimethyl-3-hydroxy-pyrid-4-one) is an orally active iron chelator investigated in various clinical trials since 1987. Dosages of 75 - 100mg/kg body weight/day of L1 have been found effective to maintain stable iron balance (urinary iron excretion of 0.5mg/kg/day) and to reduce serum ferritin levels between 6% and 25% within one year of treatment in iron-overloaded thalassemic patients. There exists long-term experience with patients who have received deferiprone continuously for more than 10 years so far. However, only few controlled comparison studies with L1 and DFO have been performed so far in order to confirm the effectiveness of deferiprone.

The main side effects encountered during a deferiprone therapy are arthropathy, gastrointestinal symptoms, headache, and mild zinc deficiency. These adverse effects are usually reversed on reducing the dose or discontinuing the drug. Except for severe joint symptoms in few patients, most of the subjects in different clinical trials have been able to continue with L1 therapy for a long-term. The most severe and rare complication following L1 administration is agranulocytosis or neutropenia.

A new treatment regimen by combining deferiprone with desferrioxamine is currently being investigated in many countries. Preliminary data could demonstrate that the combined use of both drugs is highly active showing a synergistic or even additive effect (significant decrease of serum ferritin and hepatic iron content, increase of urinary iron excretion). This synergism could be explained by the different mode of activity of the two drugs. It could be demonstrated that patients who were not sufficiently chelated with desferrioxamine or deferiprone, could achieve a negative iron balance with the combination treatment of both drugs. The combined regimen was generally well-tolerated and there is evidence that the individual toxicity profile of both drugs can be positively influenced by the simultaneous administration of L1 and DFO. The daily treatment with L1 tablets combined with a twice a week administration of parenteral desferrioxamine is more patient-convenient and therefore may enhance the compliance of the patient. In addition, this new treatment regimen will reduce the overall therapy expenses if compared to the high Desferal and material costs related to the parenteral administration of DFO on 5 to 7 days per week.

The results of the previous studies with deferiprone are often not comparable, e.g. laboratory parameters, toxicities and side effects vary from study to study. The number of patients included in the clinical investigations was in general too low to allow statistically significant evaluations. Further, there is no controlled randomized study comprising an appropriate number of patients in order to allow a comparison between the combination arm and the single agent control arms. This study protocol aims to evaluate the feasibility of the combination treatment by comparing the efficacy and safety of the combined drugs with the single agent treatment of L1 and DFO in iron-overloaded patients with thalassemia or refractory anemia in a controlled randomized multicenter study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hemochromatosis
Intervention  ICMJE
  • Drug: Deferiprone (L1)
    75 mg/kg body weight daily
  • Drug: Desferrioxamine
    In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
Study Arms  ICMJE
  • Experimental: Deferiprone + Desferrioxamine
    Interventions:
    • Drug: Deferiprone (L1)
    • Drug: Desferrioxamine
  • Experimental: Deferiprone single agent
    Intervention: Drug: Deferiprone (L1)
  • Active Comparator: Desferrioxamine single agent
    Intervention: Drug: Desferrioxamine
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 10, 2006)
95
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Iron-overloaded patients without prior iron chelation therapy as well as pretreated patients
  • Age: 4 years and older
  • Sex: male and female
  • Written informed consent

Exclusion Criteria:

  • Children < 4 years of age
  • Patients non-compliant to DFO or L1
  • Patients with known DFO or L1 toxicity/intolerance
  • Neutropenia (neutrophils < 1.5 x 10exp9/L)
  • Thrombocytopenia (platelets < 100 x 10exp9/L)
  • Renal, hepatic (liver enzymes 2.5x of upper normal level and higher) or decompensated heart failure
  • Active viral illness currently treated with interferon-alpha/ribavirin
  • Patients with repeated Yersinia infections
  • HIV-positivity
  • Pregnancy and nursing
  • Female and male of reproductive age planning for family, sexually active but not taking adequate contraceptive precaution
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 4 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Egypt,   Turkey
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00350662
Other Study ID Numbers  ICMJE DF-1
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Lipomed
Study Sponsor  ICMJE Lipomed
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Amal M El-Beshlawy, Prof. Dr. Pediatric Hospital, Cairo University, Cairo, Egypt
Principal Investigator: Yesim Aydinok, Prof. Dr. EGE University Medical School Bornova, Izmir, Turkey
PRS Account Lipomed
Verification Date November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP